A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets
Alogliptin (AGLT), active ingredient of Alogliptin Benzoate (AGLT-BZ), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes. This study aimed to build a suitable method to determine the potential related substances in AGLT-BZ bulk drug and tablets. Seven related sub...
Main Authors: | Kun Zhang, Panqin Ma, Wenna Jing, Xiangrong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-04-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087615000112 |
Similar Items
-
CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01) -
Development of a Novel, Fast, Simple HPLC Method for Determination of Atorvastatin and its Impurities in Tablets
by: Nataliia Shulyak, et al.
Published: (2021-04-01) -
Development of Methods of Quality Control of the Tablets «Ramipril»
by: Kateryna Typlynska, et al.
Published: (2023-04-01) -
PREDICTION OF ANTI-DIABETIC ALOGLIPTIN STABILITY BY ISOTHERMAL STUDIES
by: Charise Dallazem Bertol, et al.
Published: (2023-10-01) -
Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
by: Dibyalochan Mohanty, et al.
Published: (2022-07-01)